Avéli

What Avéli does

Avéli is a medical aesthetics brand operated by Revelle Aesthetics, Inc., a privately held corporation domiciled in California, USA. Its sole commercial product is the Avéli® Precision Cellulite Release Device, a hand-held, minimally invasive medical device that identifies and severs fibrous septa bands tethering the skin, the underlying structural cause of cellulite dimples on the buttocks and thighs. The three-step Identify-Release-Verify procedure is performed in a single in-office visit under local anesthesia, with the device providing real-time confirmation of septa release. Avéli is FDA-cleared for long-term reduction of cellulite in adult females and for soft tissue dissection during general and plastic surgical procedures, supported by a Multicenter Pivotal Study demonstrating efficacy through 12 months.

The company monetizes through a B2B model: it sells devices and training access to certified dermatology and plastic surgery practices, which then bill patients a one-time procedure fee. Distribution is exclusively via a US network of 700+ certified provider locations, with provider certification training and a "For Professionals" inquiry pipeline acting as the primary commercial onboarding mechanism. On the demand side, Avéli runs direct-to-consumer marketing through myaveli.com, a provider-locator tool, patient testimonials, and earned media coverage in outlets such as Allure, New Beauty, RealSelf, and The Zoe Report.

Avéli's competitive position rests on regulatory clearance, an 8-patent US portfolio plus granted patents in the EU, Japan, Mexico, Australia, and Canada, and a distribution footprint of trained providers. The company is privately held with no disclosed investors, funding history, headcount, or financials, and no evidence of acquisitions, partnerships, leadership changes, or product extensions beyond the core device.

Name

Avéli

Legal name

Revelle Aesthetics, Inc.

Website

https://myaveli.com

Company type

Private

Operating status

Operating

Short description

Avéli is a US medical aesthetics brand (Revelle Aesthetics, Inc.) that sells an FDA-cleared, hand-held device for minimally invasive, one-time release of cellulite-causing septa, distributed through 700+ certified dermatology and plastic surgery providers.

Ownership category

akta.pro rank

Product category

Aesthetic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

akta.pro secondary industry

Procedural Dermatology (Office-Based Surgery) (HLAKACAG)

Keywords

• Aesthetic medical devices
• Cellulite treatment systems
• Minimally invasive procedures
• Medical device manufacturing
• Soft tissue dissection

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Cellulite Treatment Procedure: Avéli generates revenue through medical procedure fees for its FDA-cleared cellulitis treatment. Patients pay providers for the single in-office procedure. Pricing varies based on geographic location and extent of treatment area. The company sells its medical devices to certified provider practices.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Avéli is a hand-held, minimally invasive FDA-cleared medical device (the Avéli® Precision Cellulite Release Device) that allows trained providers to identify and release the fibrous septa bands beneath the skin causing cellulite dimples on the buttocks and thighs, with real-time confirmation of release during a single in-office procedure performed under local anesthesia. The product is sold to certified dermatology and plastic surgery practices, which then perform the one-time Avéli procedure on adult female patients.

Product overview

Avéli, developed by Revelle Aesthetics, is a single-product medical device company offering the Avéli Precision Cellulite Release Device and associated one-time in-office procedure. The system is a hand-held device that guides providers to identify and release fibrous septa bands beneath the skin that cause cellulites dimples on the buttocks and thighs. The three-step procedure—Identify, Release, Verify—uses real-time confirmation to ensure complete septa release. The company also provides associated documentation (AVE001, AVE002 Instructions for Use) and has a provider network of over 700 trained locations across the U.S.

Differentiator

Problem solved

Functional benefit

Products and services

• Avéli Precision Cellulite Release Device A hand-held, minimally invasive FDA-cleared medical device sold to certified dermatology and plastic surgery practices. Providers guide it under the skin to identify and release fibrous septa bands that cause cellulite dimples on the buttocks and thighs, with real-time confirmation of septa release during the procedure.
• Avéli Cellulite Treatment Procedure A one-time, minimally invasive in-office procedure performed by certified providers using the Avéli device to release the septa bands beneath the skin that cause cellulite dimples on the buttocks and thighs. Delivered to adult female patients with long-term reduction in the appearance of cellulite, clinically demonstrated through 12 months.

Quantifiable outcome

• Clinically proven to reduce the appearance of cellulitis dimples with results demonstrated through 12 months post-procedure
• +3 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Venus Concept: Venus Concept's Venus Legacy and Venus Bliss systems target cellulite and body contouring through med-spa and aesthetics channels. Comparable in cash-pay elective model and provider-led distribution.
• Endo International (QWO): QWO was Endo's injectable collagenase treatment for cellulite dimples — the only FDA-approved injectable for cellulite before being discontinued. It competed head-to-head with Avéli for the same patient population and provider channel despite a different mechanism.
• Soliton (now part of Allergan Aesthetics): Soliton developed a Rapid Acoustic Pulse device for non-invasive improvement in cellulite appearance, later acquired by Allergan Aesthetics. Comparable to Avéli in target indication (cellulite) and aesthetics-provider channel, with a differentiated non-invasive mechanism.
• BTL Aesthetics: BTL's Emtone and VelaShape target cellulite appearance via RF and mechanical energy in dermatology and med-spa channels. Comparable in patient demographic, elective cash-pay model, and provider-led distribution.
• Cutera: Cutera's truSculpt platform offers RF-based body contouring marketed in part for cellulite appearance. Comparable in elective aesthetics channel, dermatology/plastic-surgery provider base, and capital-equipment sales model.
• Cynosure (Cellulaze): Cynosure's Cellulaze was the first FDA-cleared laser-based cellulite treatment. Although legacy, it pioneered the minimally invasive cellulite procedure category and addresses the same patient population served by Avéli.
• InMode: InMode offers Morpheus8 Body and BodyTite platforms used by dermatologists and plastic surgeons for body contouring and cellulite appearance. Comparable in provider channel, patient demographic, and elective-aesthetics demand cycle.
• Merz Aesthetics (Cellfina): Merz's Cellfina was a direct predecessor to Avéli — a minimally invasive subcision device for cellulite dimples on buttocks and thighs. Although Merz discontinued Cellfina, it remains the closest historical comparator in mechanism, indication, and provider channel.

Broad incumbents

• AbbVie (Allergan Aesthetics): Allergan Aesthetics operates the broadest medical aesthetics portfolio (Botox, CoolSculpting, Latisse, etc.) and now owns Soliton's RAP device. Comparable as the dominant incumbent serving the same dermatology/plastic-surgery customer base that Avéli targets.
• Galderma: Galderma is a global aesthetics and dermatology incumbent offering fillers, neuromodulators, and skincare sold through dermatology and plastic-surgery channels. Comparable as a broad incumbent that influences the same provider economics and patient demand for aesthetic procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/aveliofficial

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avéli